{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "15831772", "DateCompleted": {"Year": "2005", "Month": "08", "Day": "10"}, "DateRevised": {"Year": "2022", "Month": "03", "Day": "11"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "0091-2700", "JournalIssue": {"Volume": "45", "Issue": "5", "PubDate": {"Year": "2005", "Month": "May"}}, "Title": "Journal of clinical pharmacology", "ISOAbbreviation": "J Clin Pharmacol"}, "ArticleTitle": "Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development.", "Pagination": {"StartPage": "498", "EndPage": "503", "MedlinePgn": "498-503"}, "Abstract": {"AbstractText": ["This study aimed to test the utility of the ozone challenge model for profiling novel compounds designed to reduce airway inflammation. The authors used a randomized, double-dummy, double-blind, placebo-controlled 3-period crossover design alternating single orally inhaled doses of fluticasone propionate (inhaled corticosteroids, 2 mg), oral prednisolone (oral corticosteroids, 50 mg), or matched placebo. At a 2-week interval, 18 healthy ozone responders (>10% increase in sputum neutrophils) underwent a 3-hour ozone (250 ppb)/intermittent exercise challenge starting 1 hour after drug treatment. Airway inflammation was assessed at 2 hours (breath condensate) and 3 hours (induced sputum) after ozone challenge. Compared to placebo, pretreatment with inhaled corticosteroids or oral corticosteroids resulted in a significant reduction (mean [95% confidence interval]) of sputum neutrophils by 62% (35%, 77%) and 64% (39%, 79%) and of sputum supernatant myeloperoxidase by 55% (41%, 66%) and 42% (25%, 56%), respectively. The authors conclude that an optimized ozone challenge model (including ozone responders and ensuring adequate drug levels during exposure) may be useful for testing novel anti-inflammatory compounds in early development."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Hospital Grosshansdorf, Center for Pneumology and Thoracic Surgery, W\u00f6hrendamm 80, D-22927 Grosshansdorf, Germany."}], "Identifier": [], "LastName": "Holz", "ForeName": "Olaf", "Initials": "O"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Tal-Singer", "ForeName": "Ruth", "Initials": "R"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Kanniess", "ForeName": "Frank", "Initials": "F"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Simpson", "ForeName": "Kathy J", "Initials": "KJ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Gibson", "ForeName": "Anthony", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Vessey", "ForeName": "Rupert S J", "Initials": "RS"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Janicki", "ForeName": "Stanislawa", "Initials": "S"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Magnussen", "ForeName": "Helgo", "Initials": "H"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "J\u00f6rres", "ForeName": "Rudolf A", "Initials": "RA"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Richter", "ForeName": "Kai", "Initials": "K"}], "PublicationTypeList": ["Clinical Trial", "Journal Article", "Randomized Controlled Trial", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Clin Pharmacol", "NlmUniqueID": "0366372", "ISSNLinking": "0091-2700"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Androstadienes"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "9PHQ9Y1OLM", "NameOfSubstance": "Prednisolone"}, {"RegistryNumber": "CUT2W21N7U", "NameOfSubstance": "Fluticasone"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Administration, Inhalation"}, {"QualifierName": [], "DescriptorName": "Administration, Oral"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Androstadienes"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": ["methods"], "DescriptorName": "Bronchial Provocation Tests"}, {"QualifierName": [], "DescriptorName": "Cross-Over Studies"}, {"QualifierName": [], "DescriptorName": "Double-Blind Method"}, {"QualifierName": ["methods"], "DescriptorName": "Drug Evaluation"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Fluticasone"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Models, Biological"}, {"QualifierName": [], "DescriptorName": "Ozone"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Prednisolone"}, {"QualifierName": [], "DescriptorName": "Respiratory Function Tests"}, {"QualifierName": ["cytology", "metabolism"], "DescriptorName": "Sputum"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2005", "Month": "4", "Day": "16", "Hour": "9", "Minute": "0"}, {"Year": "2005", "Month": "8", "Day": "11", "Hour": "9", "Minute": "0"}, {"Year": "2005", "Month": "4", "Day": "16", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["15831772", "10.1177/0091270004273527", "45/5/498"]}}], "PubmedBookArticle": []}